...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AACR

I wonder if Zenith Epigenetics has withdrawn from the attending or presenting at the ASCO 2019 , not necessary speculating just strange if they were going ....maybe just a scheduling conflict or maybe something better. 

Share
New Message
Please login to post a reply